公开(公告)号：CA2907349A1

公开(公告)日：2014-09-18

申请号：CA2907349

申请日：2014-03-15

Applicant: CODA THERAPEUTICS INC

Inventor： PHILLIPS ANTHONY ,  EISENBUD DAVID ,  BANNAN SCOTT ,  POOL DAVID ,  MATSUOKA GROVE ,  SUNDERLAND TRACEY ,  DUFT BRADFORD

IPC: H04S5/00 ,  C12N5/00 ,  C12N5/02

Abstract: This invention concerns improved methods, uses, and kits for treating chronic wounds through the administration of anti-connexin agents, particularly anti-connexin 43 antisense polynucleotides. The methods, uses, and kits of the invention are based on the surprising and unexpected discovery that chronic wounds that do not increase or decrease in size by more than a pre-determined amount during a pre-treatment phase are more amenable to successful treatment than wounds whose size varies outside the target range during the pre-treatment phase.

公开(公告)号：WO2014145342A3

公开(公告)日：2014-12-31

申请号：PCT/US2014030082

申请日：2014-03-15

Applicant: CODA THERAPEUTICS INC

Inventor： PHILLIPS ANTHONY ,  EISENBUD DAVID ,  BANNAN SCOTT ,  POOL DAVID ,  MATSUOKA GROVE ,  SUNDERLAND TRACEY ,  DUFT BRADFORD

IPC: C12N15/11 ,  C12N5/00 ,  C12N5/02

CPC classification number: A61K31/7088 ,  A61B5/0064 ,  A61B5/0077 ,  A61B5/1072 ,  A61B5/1079 ,  A61B5/1109 ,  A61B5/445 ,  A61B5/4839 ,  A61B5/4848 ,  A61B5/7275 ,  A61B2503/40 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/70 ,  A61K31/7105 ,  A61K47/00 ,  A61K47/10 ,  A61K47/38 ,  A61K48/00 ,  C07K14/47 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2320/30 ,  C12N2320/35

Abstract: This invention concerns improved methods, uses, and kits for treating chronic wounds through the administration of anti-connexin agents, particularly anti-connexin 43 antisense polynucleotides. The methods, uses, and kits of the invention are based on the surprising and unexpected discovery that chronic wounds that do not increase or decrease in size by more than a pre-determined amount during a pre-treatment phase are more amenable to successful treatment than wounds whose size varies outside the target range during the pre-treatment phase.

Abstract translation: 本发明涉及通过施用抗连接蛋白剂，特别是抗连接蛋白43反义多核苷酸治疗慢性伤口的改进的方法，用途和试剂盒。 本发明的方法，用途和试剂盒基于惊人的和意想不到的发现，即在预处理阶段期间，不增加或减少大小超过预定量的慢性伤口比成功治疗更适合于比 在预处理阶段，其大小在目标范围之外变化的伤口。

公开(公告)号：AU2014233101A1

公开(公告)日：2015-10-15

申请号：AU2014233101

申请日：2014-03-15

Applicant: CODA THERAPEUTICS INC

Inventor： PHILLIPS ANTHONY ,  EISENBUD DAVID ,  BANNAN SCOTT ,  POOL DAVID ,  MATSUOKA GROVE ,  SUNDERLAND TRACEY ,  DUFT BRADFORD

IPC: C12N15/11 ,  C12N5/00 ,  C12N5/02

Abstract: This invention concerns improved methods, uses, and kits for treating chronic wounds through the administration of anti-connexin agents, particularly anti-connexin 43 antisense polynucleotides. The methods, uses, and kits of the invention are based on the surprising and unexpected discovery that chronic wounds that do not increase or decrease in size by more than a pre-determined amount during a pre-treatment phase are more amenable to successful treatment than wounds whose size varies outside the target range during the pre-treatment phase.

公开(公告)号：EP2970967A4

公开(公告)日：2017-04-26

申请号：EP14764924

申请日：2014-03-15

Applicant: CODA THERAPEUTICS INC

Inventor： PHILLIPS ANTHONY ,  EISENBUD DAVID ,  BANNAN SCOTT ,  POOL DAVID ,  MATSUOKA GROVE ,  SUNDERLAND TRACEY ,  DUFT BRADFORD

IPC: C12N15/113 ,  A61K31/7088

CPC classification number: A61K31/7088 ,  A61B5/0064 ,  A61B5/0077 ,  A61B5/1072 ,  A61B5/1079 ,  A61B5/1109 ,  A61B5/445 ,  A61B5/4839 ,  A61B5/4848 ,  A61B5/7275 ,  A61B2503/40 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/70 ,  A61K31/7105 ,  A61K47/00 ,  A61K47/10 ,  A61K47/38 ,  A61K48/00 ,  C07K14/47 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2320/30 ,  C12N2320/35

Abstract: This invention concerns improved methods, uses, and kits for treating chronic wounds through the administration of anti-connexin agents, particularly anti-connexin 43 antisense polynucleotides. The methods, uses, and kits of the invention are based on the surprising and unexpected discovery that chronic wounds that do not increase or decrease in size by more than a pre-determined amount during a pre-treatment phase are more amenable to successful treatment than wounds whose size varies outside the target range during the pre-treatment phase.

Abstract translation: 本发明涉及通过施用抗连接蛋白剂，特别是抗连接蛋白43反义多核苷酸治疗慢性伤口的改进的方法，用途和试剂盒。 本发明的方法，用途和试剂盒基于惊人的和意想不到的发现，即在预处理阶段期间，不增加或减少大小超过预定量的慢性伤口比成功治疗更适合于比 在预处理阶段，其大小在目标范围之外变化的伤口。